Outcomes in metastatic renal cell carcinoma (mRCC) are poor if severe systemic inflammation (SSI) is present, according to a study presented at the American Society of Clinical Oncology’s 2017 Genitourinary Cancers Symposium (abstract 530).
Wayne Harris, MD, at Winship Cancer Institute of Emory University (WCIEU), in Atlanta, Ga., and his colleagues set out to determine whether SSI can be used as a biomarker of disease progression and early death in patients with all risk levels of